Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic pharmaceutical company Mylan (NASDAQ:MYL) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Mylan and see what CAPS investors are saying about the stock right now.

Mylan facts

Headquarters (founded)

Canonsburg, Pa. (1961)

Market Cap

$11.4 billion



Trailing-12-Month Revenue

$6.8 billion


CEO Heather Bresch
CFO John Sheehan

Return on Equity (average, past 3 years)



$409.5 million / $5.7 billion


Abbott Labs
Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 569 members who have rated Mylan believe the stock will outperform the S&P 500 going forward.

Earlier this year, one of those Fools, brenoboyle, succinctly summed up the bull case for our community:

Mylan has seen and should continue to see rapidly expanding revenues due to the patent cliff and expanding prescription drug coverage. Add a robust share repurchase program and [less than] 11x forward earnings is a pittance to pay for a stock that has trounced the S&P over the past 5 years.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.